Startups
2023
NANOBOTS THERAPEUTICS SLA BIOMEDICAL COMPANY IMPROVING DRUG ACCUMULATION IN CANCER CELLS
Discovery and development of a new modality of therapeutics (MotionTx platform technology), with unique capabilities to accumulate in tumor cells
Discovery and development of a new modality of therapeutics (MotionTx platform technology), with unique capabilities to accumulate in tumor cells
Address
Carrer de Baldiri Reixac 15, 08028 Barcelona, Spain
Finance Data
CERCA ownership
Barcelona, Spain
2005
Institut de Bioenginyeria de Catalunya (IBEC)
CERCA Center Contact
ES
Eduardo SalasHead. Technology Transfer and Business Development Office
Institut de Bioenginyeria de Catalunya (IBEC)Other Catalan Public owners
Logo
Status & Deeptech areas
Company Status & Company Deeptech AreasCurrent company status
DeepTech Area
Spinoff information
Company Description
Nanobots Therapeutics is a biomedical company developing a new modality of medicines for different types of cancers, based on our unique platform technology (MotionTx).
Our mission is to develop more effective therapies for patients by increasing drug penetration into cancer cells.
We’re utilizing our proprietary MotionTx technology platform to design, engineer, and develop therapeutics that combine the high and selective tumor penetration with the precision of targeted therapies in order to reach and kill cancer cells.
The company is a spin-off of the ICREA and IBEC research center and is the result of the research led by Prof. Samuel Sánchez.
Our mission is to develop more effective therapies for patients by increasing drug penetration into cancer cells.
We’re utilizing our proprietary MotionTx technology platform to design, engineer, and develop therapeutics that combine the high and selective tumor penetration with the precision of targeted therapies in order to reach and kill cancer cells.
The company is a spin-off of the ICREA and IBEC research center and is the result of the research led by Prof. Samuel Sánchez.
Product description
What is MotionTx?
New Modality: Novel type of drugs Therapeutics In-Motion with unique tissue penetration capabilities
Platform Technology: Can carry a variety of drugs for different therapeutic indications
Targeted Delivery: Allows to cross biological barriers and selectively target cancer cells
MotionTx Platform will benefit patients by improving the accumulation of therapeutic drugs in cancer cells.
NBT-101 - Bladder Cancer
NBT-102 - Solid Tumor
New Modality: Novel type of drugs Therapeutics In-Motion with unique tissue penetration capabilities
Platform Technology: Can carry a variety of drugs for different therapeutic indications
Targeted Delivery: Allows to cross biological barriers and selectively target cancer cells
MotionTx Platform will benefit patients by improving the accumulation of therapeutic drugs in cancer cells.
NBT-101 - Bladder Cancer
NBT-102 - Solid Tumor